For treatment-naïve adults with HIV-1. See Full Indication.
96-Week Data Video For Dovato
Long-Term Phase 3 Clinical Trial Data From GEMINI 1 & 2
Benjamin Young, MD, PhD, discusses 96-week results from the GEMINI 1 & 2 trials—two phase 3 clinical trials in treatment-naïve adult patients with HIV-1. In the video, Dr. Young, Head of Global Medical Directors for ViiV Healthcare, highlights DOVATO’s durable virologic efficacy, long-term resistance results, and rates of drug-related adverse events.